Treatment efficacy and superinfection rates in complicated urinary tract infections treated with ertapenem or piperacillin tazobactam

Turkish Journal of Medical Sciences

Volumn 46, Issue 6, 2016, Pages 1760-1764

  Dizbay, Murat ^a   Özger, Hasan Selçuk ^b   Karaşahin, Ömer ^a   Karaşahin, Emine Fusun ^c  

^a GAZI UNIVERSITY   (Turkey)

^b Dr Ersin Arslan State Hospital   (Turkey)

^c Public Health Institution of Turkey   (Turkey)

Author keywords

Complicated urinary tract infection; Efficacy; Ertapenem; Piperacillin tazobactam; Superinfection

Indexed keywords

ERTAPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAM; PENICILLANIC ACID; PIPERACILLIN; TAZOBACTAM;

ADULT; AGED; ARTICLE; BLADDER CATHETERIZATION; COMPARATIVE STUDY; DRUG EFFICACY; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KLEBSIELLA; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; NEUROGENIC BLADDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PSEUDOMONAS; RECURRENT INFECTION; RETROSPECTIVE STUDY; SUPERINFECTION; URETHRA STENOSIS; URINARY TRACT CANCER; URINARY TRACT INFECTION; URINE INCONTINENCE; ANALOGS AND DERIVATIVES; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; HUMANS; PENICILLANIC ACID; PIPERACILLIN; RETROSPECTIVE STUDIES; SUPERINFECTION; TREATMENT OUTCOME;

EID: 85006752674     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: 10.3906/sag-1506-157     Document Type: Article

References (11)

1. Bader MS, Hawboldt J, Brooks A. Management of complicated urinary tract infections in the era of antimicrobial resistance. Postgrad Med 2010; 122: 7-15.
2. Hsueh PR, Hoban DJ, Carmeli Y, Chen SY, Desikan S, Alejandria M, Ko WC, Binh TQ. Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region. J Infect 2011; 63: 114-123.
3. Neal DE. Complicated urinary tract infections. Urol Clin N Am 2008; 35: 13-22.
4. Park DW, Peck KR, Chung MH, Lee JS, Park YS, Kim HY, Lee MS, Kim JY, Yeom JS, Kim MJ. Comparison of ertapenem and ceftriaxone therapy for acute pyelonephritis and other complicated urinary tract infections in Korean adults: a randomized, double-blind, multicenter trial. J Korean Med Sci, 2012; 27: 476-483.
5. Tamayo J, Orden B, Cacho J, Cuadros J, Gomes-Gorces JL, Alos JI. Activity of ertapenem and other antimicrobials against ESBL-producing enterobacteria isolated from urine in patients from Madrid. Rev Esp Quimioterap 2007; 20: 334-338.
6. Shah PM, Isaacs RD. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother 2003; 52: 538-542.
7. Tomera KM, Burdmann EA, Reyna OGP, Jiang Q, Wimmer WM, Woods GL, Gesser RM; Protocol 014 Study Group. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: result of a prospective, randomized, double-blind, multicenter study. Antimicrob Agents Chemother 2002; 46: 2895-2900.
8. Gin A, Dilay L, Karlowsky JA, Walkty A, Rubinstein E, Zhanel GG. Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination. Expert Rev Anti Infect Ther 2007; 5: 365-383.
9. Sifuentes-Osornio J, Jakob E, Clara L, Durlach R, Dain A, Ruìz-Palacios GM, Barkan L, Lamberghini R, Jáuregui A, Villalobos Y et al. Piperacillin/tazobactam in the treatment of hospitalized patients with urinary tract infections: an open non-comparative and multi-centered trial. J Chemother 1996; 8: 122-129.
10. Naber KG, Savov O, Salmen HC. Piperacillin 2g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute complicated pyelonephritis and complicated urinary tract infections. Int J Antimicrob Agents 2002; 19: 95-103.
11. Keating GM, Perry CM. Ertapenem: a review of its use in the treatment of bacterial infections. Drugs 2005; 65: 2151-2178.